{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-006554","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.118732+00:00","generated_at":"2026-06-06T18:32:02.059580+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Allarity Therapeutics amends registration rights provision in securities purchase agreement with 3i, LP","bullets":["Amendment to Securities Purchase Agreement dated Jan 18, 2024, for up to $1.54M in senior convertible notes.","Demand registration rights clarified: Purchaser can request registration starting 90 days after First Closing Date.","Company must file registration statement within 15 days of request and use best efforts to make effective within 45 days.","No other changes; original agreement remains in full force."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-006554","json":"https://secwatch.observer/filing/0001213900-24-006554.json","markdown":"https://secwatch.observer/filing/0001213900-24-006554.md","text":"https://secwatch.observer/filing/0001213900-24-006554.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024006554/0001213900-24-006554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024006554/ea192203-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T18:32:02.059580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9cd33aa2883311d7287166dde83a88f9f3d48f7f","claim":"Allarity Therapeutics, Inc. amended Amendment with 3i, LP (effective 2024-01-25).","evidence_excerpt":"On January 25, 2024, Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”) and 3i, LP, a Delaware limited partnership (the “Purchaser”), executed an amendment (the “Amendment”) to that certain Securities Purchase Agreement dated as of January 18, 2024 (the “Original Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024006554/0001213900-24-006554-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"3i, LP"},{"label":"Effective","value":"2024-01-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}